When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
THOR - Sanofi's Acquisition Enhances Its Immuno-Oncology Pipeline With Potential Game-Changing Product
Synthorx Inc.
Sanofi (SNY) announced that it had acquiredSynthorx, Inc. (THOR) for approximately $68 per share in cash, for a total value of $2.5 billion. This is a solid deal for Sanofi, because it will allow the company to obtain a drug known as THOR-707, which holds promise as a next generation immuno-oncology product. Not only does Synthorx's drug THOR-707 hold the capability to treat oncology indications, but it has another focus of treating autoimmune disorders as well. This means Sanofi gets the best of both worlds when it comes to acquiring